A large percentage of patients prescribed the biotech's lone drug stop taking it early. Can two changes to its dosing protocols solve that problem? An alarming number of patients prescribed Nerlynx -- ...
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results